#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=On the integrity of functional brain networks in schizophrenia, Parkinson ’ s disease, and advanced age: Evidence from connectivity-based single-subject classification Previous whole-brain functional connectivity studies achieved successful classifications of patients and healthy controls but only offered limited specificity as to affected brain systems.
1-1	0-2	On	_
1-2	3-6	the	_
1-3	7-16	integrity	_
1-4	17-19	of	_
1-5	20-30	functional	_
1-6	31-36	brain	_
1-7	37-45	networks	_
1-8	46-48	in	_
1-9	49-62	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-10	63-64	,	_
1-11	65-74	Parkinson	http://maven.renci.org/NeuroBridge/neurobridge#Parkinsonism
1-12	75-76	’	_
1-13	77-78	s	_
1-14	79-86	disease	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
1-15	87-88	,	_
1-16	89-92	and	_
1-17	93-101	advanced	_
1-18	102-105	age	_
1-19	106-107	:	_
1-20	108-116	Evidence	_
1-21	117-121	from	_
1-22	122-140	connectivity-based	_
1-23	141-155	single-subject	_
1-24	156-170	classification	_
1-25	171-179	Previous	_
1-26	180-191	whole-brain	_
1-27	192-202	functional	_
1-28	203-215	connectivity	_
1-29	216-223	studies	_
1-30	224-232	achieved	_
1-31	233-243	successful	_
1-32	244-259	classifications	_
1-33	260-262	of	_
1-34	263-271	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-35	272-275	and	_
1-36	276-283	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
1-37	284-292	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
1-38	293-296	but	_
1-39	297-301	only	_
1-40	302-309	offered	_
1-41	310-317	limited	_
1-42	318-329	specificity	_
1-43	330-332	as	_
1-44	333-335	to	_
1-45	336-344	affected	_
1-46	345-350	brain	_
1-47	351-358	systems	_
1-48	359-360	.	_

Text=Here, we examined whether the connectivity patterns of functional systems affected in schizophrenia (SCZ), Parkinson ’ s disease (PD), or normal aging equally translate into high classification accuracies for these conditions.
2-1	361-365	Here	_
2-2	366-367	,	_
2-3	368-370	we	_
2-4	371-379	examined	_
2-5	380-387	whether	_
2-6	388-391	the	_
2-7	392-404	connectivity	_
2-8	405-413	patterns	_
2-9	414-416	of	_
2-10	417-427	functional	_
2-11	428-435	systems	_
2-12	436-444	affected	_
2-13	445-447	in	_
2-14	448-461	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-15	462-463	(	_
2-16	464-467	SCZ	_
2-17	468-469	)	_
2-18	470-471	,	_
2-19	472-481	Parkinson	_
2-20	482-483	’	_
2-21	484-485	s	_
2-22	486-493	disease	_
2-23	494-495	(	_
2-24	496-498	PD	_
2-25	499-500	)	_
2-26	501-502	,	_
2-27	503-505	or	_
2-28	506-512	normal	_
2-29	513-518	aging	_
2-30	519-526	equally	_
2-31	527-536	translate	_
2-32	537-541	into	_
2-33	542-546	high	_
2-34	547-561	classification	_
2-35	562-572	accuracies	_
2-36	573-576	for	_
2-37	577-582	these	_
2-38	583-593	conditions	_
2-39	594-595	.	_

Text=We compared classification performance between pre-defined networks for each group and, for any given network, between groups.
3-1	596-598	We	_
3-2	599-607	compared	_
3-3	608-622	classification	_
3-4	623-634	performance	_
3-5	635-642	between	_
3-6	643-654	pre-defined	_
3-7	655-663	networks	_
3-8	664-667	for	_
3-9	668-672	each	_
3-10	673-678	group	_
3-11	679-682	and	_
3-12	683-684	,	_
3-13	685-688	for	_
3-14	689-692	any	_
3-15	693-698	given	_
3-16	699-706	network	_
3-17	707-708	,	_
3-18	709-716	between	_
3-19	717-723	groups	_
3-20	724-725	.	_

Text=Separate support vector machine classifications of 86 SCZ patients, 80 PD patients, and 95 older adults relative to their matched healthy/young controls, respectively, were performed on functional connectivity in 12 task-based, meta-analytically defined networks using 25 replications of a nested 10-fold cross-validation scheme.
4-1	726-734	Separate	_
4-2	735-742	support	_
4-3	743-749	vector	_
4-4	750-757	machine	_
4-5	758-773	classifications	_
4-6	774-776	of	_
4-7	777-779	86	_
4-8	780-783	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-9	784-792	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-10	793-794	,	_
4-11	795-797	80	_
4-12	798-800	PD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-13	801-809	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
4-14	810-811	,	_
4-15	812-815	and	_
4-16	816-818	95	_
4-17	819-824	older	_
4-18	825-831	adults	_
4-19	832-840	relative	_
4-20	841-843	to	_
4-21	844-849	their	_
4-22	850-857	matched	_
4-23	858-871	healthy/young	_
4-24	872-880	controls	_
4-25	881-882	,	_
4-26	883-895	respectively	_
4-27	896-897	,	_
4-28	898-902	were	_
4-29	903-912	performed	_
4-30	913-915	on	_
4-31	916-926	functional	_
4-32	927-939	connectivity	_
4-33	940-942	in	_
4-34	943-945	12	_
4-35	946-956	task-based	_
4-36	957-958	,	_
4-37	959-976	meta-analytically	_
4-38	977-984	defined	_
4-39	985-993	networks	_
4-40	994-999	using	_
4-41	1000-1002	25	_
4-42	1003-1015	replications	_
4-43	1016-1018	of	_
4-44	1019-1020	a	_
4-45	1021-1027	nested	_
4-46	1028-1035	10-fold	_
4-47	1036-1052	cross-validation	_
4-48	1053-1059	scheme	_
4-49	1060-1061	.	_

Text=Classification performance of the various networks clearly differed between conditions, as those networks that best classified one disease were usually non-informative for the other.
5-1	1062-1076	Classification	_
5-2	1077-1088	performance	_
5-3	1089-1091	of	_
5-4	1092-1095	the	_
5-5	1096-1103	various	_
5-6	1104-1112	networks	_
5-7	1113-1120	clearly	_
5-8	1121-1129	differed	_
5-9	1130-1137	between	_
5-10	1138-1148	conditions	_
5-11	1149-1150	,	_
5-12	1151-1153	as	_
5-13	1154-1159	those	_
5-14	1160-1168	networks	_
5-15	1169-1173	that	_
5-16	1174-1178	best	_
5-17	1179-1189	classified	_
5-18	1190-1193	one	_
5-19	1194-1201	disease	_
5-20	1202-1206	were	_
5-21	1207-1214	usually	_
5-22	1215-1230	non-informative	_
5-23	1231-1234	for	_
5-24	1235-1238	the	_
5-25	1239-1244	other	_
5-26	1245-1246	.	_

Text=For SCZ, but not PD, emotion-processing, empathy, and cognitive action-control networks distinguished patients most accurately from controls.
6-1	1247-1250	For	_
6-2	1251-1254	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-3	1255-1256	,	_
6-4	1257-1260	but	_
6-5	1261-1264	not	_
6-6	1265-1267	PD	_
6-7	1268-1269	,	_
6-8	1270-1288	emotion-processing	_
6-9	1289-1290	,	_
6-10	1291-1298	empathy	_
6-11	1299-1300	,	_
6-12	1301-1304	and	_
6-13	1305-1314	cognitive	_
6-14	1315-1329	action-control	_
6-15	1330-1338	networks	_
6-16	1339-1352	distinguished	_
6-17	1353-1361	patients	_
6-18	1362-1366	most	_
6-19	1367-1377	accurately	_
6-20	1378-1382	from	_
6-21	1383-1391	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
6-22	1392-1393	.	_

Text=For PD, but not SCZ, networks subserving autobiographical or semantic memory, motor execution, and theory-of-mind cognition yielded the best classifications.
7-1	1394-1397	For	_
7-2	1398-1400	PD	_
7-3	1401-1402	,	_
7-4	1403-1406	but	_
7-5	1407-1410	not	_
7-6	1411-1414	SCZ	_
7-7	1415-1416	,	_
7-8	1417-1425	networks	_
7-9	1426-1436	subserving	_
7-10	1437-1453	autobiographical	_
7-11	1454-1456	or	_
7-12	1457-1465	semantic	_
7-13	1466-1472	memory	_
7-14	1473-1474	,	_
7-15	1475-1480	motor	_
7-16	1481-1490	execution	_
7-17	1491-1492	,	_
7-18	1493-1496	and	_
7-19	1497-1511	theory-of-mind	_
7-20	1512-1521	cognition	_
7-21	1522-1529	yielded	_
7-22	1530-1533	the	_
7-23	1534-1538	best	_
7-24	1539-1554	classifications	_
7-25	1555-1556	.	_

Text=In contrast, young–old classification was excellent based on all networks and outperformed both clinical classifications.
8-1	1557-1559	In	_
8-2	1560-1568	contrast	_
8-3	1569-1570	,	_
8-4	1571-1580	young–old	_
8-5	1581-1595	classification	_
8-6	1596-1599	was	_
8-7	1600-1609	excellent	_
8-8	1610-1615	based	_
8-9	1616-1618	on	_
8-10	1619-1622	all	_
8-11	1623-1631	networks	_
8-12	1632-1635	and	_
8-13	1636-1648	outperformed	_
8-14	1649-1653	both	_
8-15	1654-1662	clinical	_
8-16	1663-1678	classifications	_
8-17	1679-1680	.	_

Text=Our pattern-classification approach captured associations between clinical and developmental conditions and functional network integrity with a higher level of specificity than did previous whole-brain analyses.
9-1	1681-1684	Our	_
9-2	1685-1707	pattern-classification	_
9-3	1708-1716	approach	_
9-4	1717-1725	captured	_
9-5	1726-1738	associations	_
9-6	1739-1746	between	_
9-7	1747-1755	clinical	_
9-8	1756-1759	and	_
9-9	1760-1773	developmental	_
9-10	1774-1784	conditions	_
9-11	1785-1788	and	_
9-12	1789-1799	functional	_
9-13	1800-1807	network	_
9-14	1808-1817	integrity	_
9-15	1818-1822	with	_
9-16	1823-1824	a	_
9-17	1825-1831	higher	_
9-18	1832-1837	level	_
9-19	1838-1840	of	_
9-20	1841-1852	specificity	_
9-21	1853-1857	than	_
9-22	1858-1861	did	_
9-23	1862-1870	previous	_
9-24	1871-1882	whole-brain	_
9-25	1883-1891	analyses	_
9-26	1892-1893	.	_

Text=Taken together, our results support resting-state connectivity as a marker of functional dysregulation in specific networks known to be affected by SCZ and PD, while suggesting that aging affects network integrity in a more global way.
10-1	1894-1899	Taken	_
10-2	1900-1908	together	_
10-3	1909-1910	,	_
10-4	1911-1914	our	_
10-5	1915-1922	results	_
10-6	1923-1930	support	_
10-7	1931-1944	resting-state	_
10-8	1945-1957	connectivity	_
10-9	1958-1960	as	_
10-10	1961-1962	a	_
10-11	1963-1969	marker	_
10-12	1970-1972	of	_
10-13	1973-1983	functional	_
10-14	1984-1997	dysregulation	_
10-15	1998-2000	in	_
10-16	2001-2009	specific	_
10-17	2010-2018	networks	_
10-18	2019-2024	known	_
10-19	2025-2027	to	_
10-20	2028-2030	be	_
10-21	2031-2039	affected	_
10-22	2040-2042	by	_
10-23	2043-2046	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-24	2047-2050	and	_
10-25	2051-2053	PD	_
10-26	2054-2055	,	_
10-27	2056-2061	while	_
10-28	2062-2072	suggesting	_
10-29	2073-2077	that	_
10-30	2078-2083	aging	_
10-31	2084-2091	affects	_
10-32	2092-2099	network	_
10-33	2100-2109	integrity	_
10-34	2110-2112	in	_
10-35	2113-2114	a	_
10-36	2115-2119	more	_
10-37	2120-2126	global	_
10-38	2127-2130	way	_
10-39	2131-2132	.	_

Text=2.
11-1	2133-2134	2	_
11-2	2135-2136	.	_

Text=MATERIALS AND METHODS 2.1 Samples Schizophrenia Resting-state (RS) functional magnetic resonance imaging (fMRI) data and phenotypical information of 86 SCZ patients and 84 HCs obtained from the COBRE sample (http: //fcon_1000.projects.nitrc.org/indi/retro/cobre.html) and the University Hospital of Göttingen, Germany, were included in the analysis.
12-1	2137-2146	MATERIALS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-2	2147-2150	AND	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-3	2151-2158	METHODS	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
12-4	2159-2162	2.1	_
12-5	2163-2170	Samples	_
12-6	2171-2184	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-7	2185-2198	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-8	2199-2200	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-9	2201-2203	RS	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-10	2204-2205	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-11	2206-2216	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
12-12	2217-2225	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
12-13	2226-2235	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
12-14	2236-2243	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
12-15	2244-2245	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
12-16	2246-2250	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
12-17	2251-2252	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
12-18	2253-2257	data	_
12-19	2258-2261	and	_
12-20	2262-2274	phenotypical	_
12-21	2275-2286	information	_
12-22	2287-2289	of	_
12-23	2290-2292	86	_
12-24	2293-2296	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-25	2297-2305	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-26	2306-2309	and	_
12-27	2310-2312	84	_
12-28	2313-2316	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
12-29	2317-2325	obtained	_
12-30	2326-2330	from	_
12-31	2331-2334	the	_
12-32	2335-2340	COBRE	_
12-33	2341-2347	sample	_
12-34	2348-2349	(	_
12-35	2350-2354	http	_
12-36	2355-2356	:	_
12-37	2357-2409	//fcon_1000.projects.nitrc.org/indi/retro/cobre.html	_
12-38	2410-2411	)	_
12-39	2412-2415	and	_
12-40	2416-2419	the	_
12-41	2420-2430	University	_
12-42	2431-2439	Hospital	_
12-43	2440-2442	of	_
12-44	2443-2452	Göttingen	_
12-45	2453-2454	,	_
12-46	2455-2462	Germany	_
12-47	2463-2464	,	_
12-48	2465-2469	were	_
12-49	2470-2478	included	_
12-50	2479-2481	in	_
12-51	2482-2485	the	_
12-52	2486-2494	analysis	_
12-53	2495-2496	.	_

Text=SCZ diagnosis was assigned as assessed by the DSM-IV-TR based on the structured clinical interview (SCID-P) and the International Classification of Diseases (ICD-10), respectively.
13-1	2497-2500	SCZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-2	2501-2510	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-3	2511-2514	was	_
13-4	2515-2523	assigned	_
13-5	2524-2526	as	_
13-6	2527-2535	assessed	_
13-7	2536-2538	by	_
13-8	2539-2542	the	_
13-9	2543-2552	DSM-IV-TR	_
13-10	2553-2558	based	_
13-11	2559-2561	on	_
13-12	2562-2565	the	_
13-13	2566-2576	structured	_
13-14	2577-2585	clinical	_
13-15	2586-2595	interview	_
13-16	2596-2597	(	_
13-17	2598-2604	SCID-P	_
13-18	2605-2606	)	_
13-19	2607-2610	and	_
13-20	2611-2614	the	_
13-21	2615-2628	International	_
13-22	2629-2643	Classification	_
13-23	2644-2646	of	_
13-24	2647-2655	Diseases	_
13-25	2656-2657	(	_
13-26	2658-2664	ICD-10	_
13-27	2665-2666	)	_
13-28	2667-2668	,	_
13-29	2669-2681	respectively	_
13-30	2682-2683	.	_

Text=SCZ symptom severity was assed using the Positive and Negative Symptom Scale (PANSS) evaluating the severity of positive and negative symptoms as well as the general psychopathology.
14-1	2684-2687	SCZ	_
14-2	2688-2695	symptom	_
14-3	2696-2704	severity	_
14-4	2705-2708	was	_
14-5	2709-2714	assed	_
14-6	2715-2720	using	_
14-7	2721-2724	the	_
14-8	2725-2733	Positive	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
14-9	2734-2737	and	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
14-10	2738-2746	Negative	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
14-11	2747-2754	Symptom	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
14-12	2755-2760	Scale	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
14-13	2761-2762	(	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
14-14	2763-2768	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
14-15	2769-2770	)	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale
14-16	2771-2781	evaluating	_
14-17	2782-2785	the	_
14-18	2786-2794	severity	_
14-19	2795-2797	of	_
14-20	2798-2806	positive	_
14-21	2807-2810	and	_
14-22	2811-2819	negative	_
14-23	2820-2828	symptoms	_
14-24	2829-2831	as	_
14-25	2832-2836	well	_
14-26	2837-2839	as	_
14-27	2840-2843	the	_
14-28	2844-2851	general	_
14-29	2852-2867	psychopathology	_
14-30	2868-2869	.	_

Text=Patients received their regular medication therapy with considerable variability in the exact compounds used and a high prevalence of combination drug therapy (medicated patients but exact medication and dose unknown for Olanzapine equivalent dose: COBRE: 50,9%; Göttingen: 25,8%; medication status unknown: COBRE: 1 SCZ patient; Göttingen: 2 SCZ patients).
15-1	2870-2878	Patients	_
15-2	2879-2887	received	_
15-3	2888-2893	their	_
15-4	2894-2901	regular	_
15-5	2902-2912	medication	_
15-6	2913-2920	therapy	_
15-7	2921-2925	with	_
15-8	2926-2938	considerable	_
15-9	2939-2950	variability	_
15-10	2951-2953	in	_
15-11	2954-2957	the	_
15-12	2958-2963	exact	_
15-13	2964-2973	compounds	_
15-14	2974-2978	used	_
15-15	2979-2982	and	_
15-16	2983-2984	a	_
15-17	2985-2989	high	_
15-18	2990-3000	prevalence	_
15-19	3001-3003	of	_
15-20	3004-3015	combination	_
15-21	3016-3020	drug	_
15-22	3021-3028	therapy	_
15-23	3029-3030	(	_
15-24	3031-3040	medicated	_
15-25	3041-3049	patients	_
15-26	3050-3053	but	_
15-27	3054-3059	exact	_
15-28	3060-3070	medication	_
15-29	3071-3074	and	_
15-30	3075-3079	dose	_
15-31	3080-3087	unknown	_
15-32	3088-3091	for	_
15-33	3092-3102	Olanzapine	_
15-34	3103-3113	equivalent	_
15-35	3114-3118	dose	_
15-36	3119-3120	:	_
15-37	3121-3126	COBRE	_
15-38	3127-3128	:	_
15-39	3129-3133	50,9	_
15-40	3134-3135	%	_
15-41	3136-3137	;	_
15-42	3138-3147	Göttingen	_
15-43	3148-3149	:	_
15-44	3150-3154	25,8	_
15-45	3155-3156	%	_
15-46	3157-3158	;	_
15-47	3159-3169	medication	_
15-48	3170-3176	status	_
15-49	3177-3184	unknown	_
15-50	3185-3186	:	_
15-51	3187-3192	COBRE	_
15-52	3193-3194	:	_
15-53	3195-3196	1	_
15-54	3197-3200	SCZ	_
15-55	3201-3208	patient	_
15-56	3209-3210	;	_
15-57	3211-3220	Göttingen	_
15-58	3221-3222	:	_
15-59	3223-3224	2	_
15-60	3225-3228	SCZ	_
15-61	3229-3237	patients	_
15-62	3238-3239	)	_
15-63	3240-3241	.	_

Text=Parkinson ’ s disease RS fMRI data of 80 PD patients and 84 HCs obtained from the RWTH Aachen University Hospital and the University Hospital Düsseldorf, Germany, were included in the analysis.
16-1	3242-3251	Parkinson	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
16-2	3252-3253	’	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
16-3	3254-3255	s	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
16-4	3256-3263	disease	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
16-5	3264-3266	RS	_
16-6	3267-3271	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
16-7	3272-3276	data	_
16-8	3277-3279	of	_
16-9	3280-3282	80	_
16-10	3283-3285	PD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-11	3286-3294	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-12	3295-3298	and	_
16-13	3299-3301	84	_
16-14	3302-3305	HCs	http://maven.renci.org/NeuroBridge/neurobridge#Thing
16-15	3306-3314	obtained	_
16-16	3315-3319	from	_
16-17	3320-3323	the	_
16-18	3324-3328	RWTH	_
16-19	3329-3335	Aachen	_
16-20	3336-3346	University	_
16-21	3347-3355	Hospital	_
16-22	3356-3359	and	_
16-23	3360-3363	the	_
16-24	3364-3374	University	_
16-25	3375-3383	Hospital	_
16-26	3384-3394	Düsseldorf	_
16-27	3395-3396	,	_
16-28	3397-3404	Germany	_
16-29	3405-3406	,	_
16-30	3407-3411	were	_
16-31	3412-3420	included	_
16-32	3421-3423	in	_
16-33	3424-3427	the	_
16-34	3428-3436	analysis	_
16-35	3437-3438	.	_

Text=Diagnosis of PD was assigned by consultant neurologists with longstanding expertise in movement disorders based on clinical examination and review of the medical history.
17-1	3439-3448	Diagnosis	_
17-2	3449-3451	of	_
17-3	3452-3454	PD	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
17-4	3455-3458	was	_
17-5	3459-3467	assigned	_
17-6	3468-3470	by	_
17-7	3471-3481	consultant	_
17-8	3482-3494	neurologists	_
17-9	3495-3499	with	_
17-10	3500-3512	longstanding	_
17-11	3513-3522	expertise	_
17-12	3523-3525	in	_
17-13	3526-3534	movement	_
17-14	3535-3544	disorders	_
17-15	3545-3550	based	_
17-16	3551-3553	on	_
17-17	3554-3562	clinical	_
17-18	3563-3574	examination	_
17-19	3575-3578	and	_
17-20	3579-3585	review	_
17-21	3586-3588	of	_
17-22	3589-3592	the	_
17-23	3593-3600	medical	_
17-24	3601-3608	history	_
17-25	3609-3610	.	_

Text=Included PD patients fulfilled the standard UK Brain Bank criteria for PD and had on average a mild cognitive impairment as confirmed by the Montreal Cognitive Assessment (MoCA) but no major depression symptoms.
18-1	3611-3619	Included	_
18-2	3620-3622	PD	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
18-3	3623-3631	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
18-4	3632-3641	fulfilled	_
18-5	3642-3645	the	_
18-6	3646-3654	standard	_
18-7	3655-3657	UK	_
18-8	3658-3663	Brain	_
18-9	3664-3668	Bank	_
18-10	3669-3677	criteria	_
18-11	3678-3681	for	_
18-12	3682-3684	PD	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
18-13	3685-3688	and	_
18-14	3689-3692	had	_
18-15	3693-3695	on	_
18-16	3696-3703	average	_
18-17	3704-3705	a	_
18-18	3706-3710	mild	_
18-19	3711-3720	cognitive	_
18-20	3721-3731	impairment	_
18-21	3732-3734	as	_
18-22	3735-3744	confirmed	_
18-23	3745-3747	by	_
18-24	3748-3751	the	_
18-25	3752-3760	Montreal	_
18-26	3761-3770	Cognitive	_
18-27	3771-3781	Assessment	_
18-28	3782-3783	(	_
18-29	3784-3788	MoCA	_
18-30	3789-3790	)	_
18-31	3791-3794	but	_
18-32	3795-3797	no	_
18-33	3798-3803	major	_
18-34	3804-3814	depression	_
18-35	3815-3823	symptoms	_
18-36	3824-3825	.	_

Text=To assess PD symptom severity and evaluate motor impairments the Unified Parkinson ’ s disease Rating Scale Part III (UPDRS) and Hoehn and Yahr Scale (H & Y Scale) were applied.
19-1	3826-3828	To	_
19-2	3829-3835	assess	_
19-3	3836-3838	PD	_
19-4	3839-3846	symptom	_
19-5	3847-3855	severity	_
19-6	3856-3859	and	_
19-7	3860-3868	evaluate	_
19-8	3869-3874	motor	_
19-9	3875-3886	impairments	_
19-10	3887-3890	the	_
19-11	3891-3898	Unified	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
19-12	3899-3908	Parkinson	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
19-13	3909-3910	’	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
19-14	3911-3912	s	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
19-15	3913-3920	disease	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
19-16	3921-3927	Rating	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
19-17	3928-3933	Scale	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
19-18	3934-3938	Part	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
19-19	3939-3942	III	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
19-20	3943-3944	(	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
19-21	3945-3950	UPDRS	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
19-22	3951-3952	)	http://maven.renci.org/NeuroBridge/neurobridge#Parkinson'sDisease
19-23	3953-3956	and	_
19-24	3957-3962	Hoehn	http://maven.renci.org/NeuroBridge/neurobridge#Scale
19-25	3963-3966	and	http://maven.renci.org/NeuroBridge/neurobridge#Scale
19-26	3967-3971	Yahr	http://maven.renci.org/NeuroBridge/neurobridge#Scale
19-27	3972-3977	Scale	http://maven.renci.org/NeuroBridge/neurobridge#Scale
19-28	3978-3979	(	http://maven.renci.org/NeuroBridge/neurobridge#Scale
19-29	3980-3981	H	http://maven.renci.org/NeuroBridge/neurobridge#Scale
19-30	3982-3983	&	http://maven.renci.org/NeuroBridge/neurobridge#Scale
19-31	3984-3985	Y	_
19-32	3986-3991	Scale	http://maven.renci.org/NeuroBridge/neurobridge#Scale
19-33	3992-3993	)	http://maven.renci.org/NeuroBridge/neurobridge#Scale
19-34	3994-3998	were	_
19-35	3999-4006	applied	_
19-36	4007-4008	.	_

Text=All patients were medicated with their regular individual PD-related treatment (medication and dose unknown for Levodopa equivalent daily dose: RWTH Aachen: 28,1%; HHU Düsseldorf: 12,5%).
20-1	4009-4012	All	_
20-2	4013-4021	patients	_
20-3	4022-4026	were	_
20-4	4027-4036	medicated	_
20-5	4037-4041	with	_
20-6	4042-4047	their	_
20-7	4048-4055	regular	_
20-8	4056-4066	individual	_
20-9	4067-4077	PD-related	_
20-10	4078-4087	treatment	_
20-11	4088-4089	(	_
20-12	4090-4100	medication	_
20-13	4101-4104	and	_
20-14	4105-4109	dose	_
20-15	4110-4117	unknown	_
20-16	4118-4121	for	_
20-17	4122-4130	Levodopa	_
20-18	4131-4141	equivalent	_
20-19	4142-4147	daily	_
20-20	4148-4152	dose	_
20-21	4153-4154	:	_
20-22	4155-4159	RWTH	_
20-23	4160-4166	Aachen	_
20-24	4167-4168	:	_
20-25	4169-4173	28,1	_
20-26	4174-4175	%	_
20-27	4176-4177	;	_
20-28	4178-4181	HHU	_
20-29	4182-4192	Düsseldorf	_
20-30	4193-4194	:	_
20-31	4195-4199	12,5	_
20-32	4200-4201	%	_
20-33	4202-4203	)	_
20-34	4204-4205	.	_

Text=Healthy controls (HC) RS fMRI data of HC (HCSCZ and HCPD) were obtained from the four different sites as respective clinical subjects (SCZ and PD), and were without any record of neurological or psychiatric disorders as confirmed via structured clinical screening (SCID).
21-1	4206-4213	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
21-2	4214-4222	controls	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
21-3	4223-4224	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
21-4	4225-4227	HC	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
21-5	4228-4229	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
21-6	4230-4232	RS	_
21-7	4233-4237	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
21-8	4238-4242	data	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
21-9	4243-4245	of	_
21-10	4246-4248	HC	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
21-11	4249-4250	(	_
21-12	4251-4256	HCSCZ	http://maven.renci.org/NeuroBridge/neurobridge#ChronicSchizophrenia
21-13	4257-4260	and	_
21-14	4261-4265	HCPD	http://maven.renci.org/NeuroBridge/neurobridge#Thing
21-15	4266-4267	)	_
21-16	4268-4272	were	_
21-17	4273-4281	obtained	_
21-18	4282-4286	from	_
21-19	4287-4290	the	_
21-20	4291-4295	four	_
21-21	4296-4305	different	_
21-22	4306-4311	sites	_
21-23	4312-4314	as	_
21-24	4315-4325	respective	_
21-25	4326-4334	clinical	_
21-26	4335-4343	subjects	_
21-27	4344-4345	(	_
21-28	4346-4349	SCZ	_
21-29	4350-4353	and	_
21-30	4354-4356	PD	_
21-31	4357-4358	)	_
21-32	4359-4360	,	_
21-33	4361-4364	and	_
21-34	4365-4369	were	_
21-35	4370-4377	without	_
21-36	4378-4381	any	_
21-37	4382-4388	record	_
21-38	4389-4391	of	_
21-39	4392-4404	neurological	_
21-40	4405-4407	or	_
21-41	4408-4419	psychiatric	_
21-42	4420-4429	disorders	_
21-43	4430-4432	as	_
21-44	4433-4442	confirmed	_
21-45	4443-4446	via	_
21-46	4447-4457	structured	_
21-47	4458-4466	clinical	_
21-48	4467-4476	screening	_
21-49	4477-4478	(	_
21-50	4479-4483	SCID	_
21-51	4484-4485	)	_
21-52	4486-4487	.	_

Text=Normal Aging RS fMRI data of 95 old (age range: 55 – 70 years) and 93 young (age range: 20 – 35 years) participants with an age range of 15 years in each group were obtained from the population-based 1000BRAINS study and another separate study at the Research Centre Jülich, Germany.
22-1	4488-4494	Normal	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-2	4495-4500	Aging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-3	4501-4503	RS	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-4	4504-4508	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-5	4509-4513	data	_
22-6	4514-4516	of	_
22-7	4517-4519	95	_
22-8	4520-4523	old	_
22-9	4524-4525	(	_
22-10	4526-4529	age	_
22-11	4530-4535	range	_
22-12	4536-4537	:	_
22-13	4538-4540	55	_
22-14	4541-4542	–	_
22-15	4543-4545	70	_
22-16	4546-4551	years	_
22-17	4552-4553	)	_
22-18	4554-4557	and	_
22-19	4558-4560	93	_
22-20	4561-4566	young	_
22-21	4567-4568	(	_
22-22	4569-4572	age	_
22-23	4573-4578	range	_
22-24	4579-4580	:	_
22-25	4581-4583	20	_
22-26	4584-4585	–	_
22-27	4586-4588	35	_
22-28	4589-4594	years	_
22-29	4595-4596	)	_
22-30	4597-4609	participants	_
22-31	4610-4614	with	_
22-32	4615-4617	an	_
22-33	4618-4621	age	_
22-34	4622-4627	range	_
22-35	4628-4630	of	_
22-36	4631-4633	15	_
22-37	4634-4639	years	_
22-38	4640-4642	in	_
22-39	4643-4647	each	_
22-40	4648-4653	group	_
22-41	4654-4658	were	_
22-42	4659-4667	obtained	_
22-43	4668-4672	from	_
22-44	4673-4676	the	_
22-45	4677-4693	population-based	_
22-46	4694-4704	1000BRAINS	_
22-47	4705-4710	study	_
22-48	4711-4714	and	_
22-49	4715-4722	another	_
22-50	4723-4731	separate	_
22-51	4732-4737	study	_
22-52	4738-4740	at	_
22-53	4741-4744	the	_
22-54	4745-4753	Research	_
22-55	4754-4760	Centre	_
22-56	4761-4767	Jülich	_
22-57	4768-4769	,	_
22-58	4770-4777	Germany	_
22-59	4778-4779	.	_

Text=This relative small age-range aims to enhance the subsample homogeneity.
23-1	4780-4784	This	_
23-2	4785-4793	relative	_
23-3	4794-4799	small	_
23-4	4800-4809	age-range	_
23-5	4810-4814	aims	_
23-6	4815-4817	to	_
23-7	4818-4825	enhance	_
23-8	4826-4829	the	_
23-9	4830-4839	subsample	_
23-10	4840-4851	homogeneity	_
23-11	4852-4853	.	_

Text=“ Normal aging ” in old participants refers to the absence of neurodegenerative diseases.
24-1	4854-4855	“	_
24-2	4856-4862	Normal	_
24-3	4863-4868	aging	_
24-4	4869-4870	”	_
24-5	4871-4873	in	_
24-6	4874-4877	old	_
24-7	4878-4890	participants	_
24-8	4891-4897	refers	_
24-9	4898-4900	to	_
24-10	4901-4904	the	_
24-11	4905-4912	absence	_
24-12	4913-4915	of	_
24-13	4916-4933	neurodegenerative	_
24-14	4934-4942	diseases	_
24-15	4943-4944	.	_

Text=Older adults showed cognitive performance adequate for their age (DemTect> 13) as assessed by the Mild Cognitive Impairment and Early Dementia Detection (DemTect) assessment and all participants did not exhibit clinically relevant symptoms for depression (BDI-II <13) as evaluated via the Beck Depression Inventory-II.
25-1	4945-4950	Older	_
25-2	4951-4957	adults	_
25-3	4958-4964	showed	_
25-4	4965-4974	cognitive	_
25-5	4975-4986	performance	_
25-6	4987-4995	adequate	_
25-7	4996-4999	for	_
25-8	5000-5005	their	_
25-9	5006-5009	age	_
25-10	5010-5011	(	_
25-11	5012-5019	DemTect	_
25-12	5020-5021	>	_
25-13	5022-5024	13	_
25-14	5025-5026	)	_
25-15	5027-5029	as	_
25-16	5030-5038	assessed	_
25-17	5039-5041	by	_
25-18	5042-5045	the	_
25-19	5046-5050	Mild	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
25-20	5051-5060	Cognitive	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
25-21	5061-5071	Impairment	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
25-22	5072-5075	and	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
25-23	5076-5081	Early	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
25-24	5082-5090	Dementia	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
25-25	5091-5100	Detection	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
25-26	5101-5102	(	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
25-27	5103-5110	DemTect	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
25-28	5111-5112	)	http://maven.renci.org/NeuroBridge/neurobridge#MildCognitiveDisorder
25-29	5113-5123	assessment	_
25-30	5124-5127	and	_
25-31	5128-5131	all	_
25-32	5132-5144	participants	_
25-33	5145-5148	did	_
25-34	5149-5152	not	_
25-35	5153-5160	exhibit	_
25-36	5161-5171	clinically	_
25-37	5172-5180	relevant	_
25-38	5181-5189	symptoms	_
25-39	5190-5193	for	_
25-40	5194-5204	depression	_
25-41	5205-5206	(	_
25-42	5207-5213	BDI-II	_
25-43	5214-5215	<	_
25-44	5216-5218	13	_
25-45	5219-5220	)	_
25-46	5221-5223	as	_
25-47	5224-5233	evaluated	_
25-48	5234-5237	via	_
25-49	5238-5241	the	_
25-50	5242-5246	Beck	_
25-51	5247-5257	Depression	_
25-52	5258-5270	Inventory-II	_
25-53	5271-5272	.	_

Text=Importantly, target and control groups (i.e., patients vs. healthy controls, old vs. young adults) of all three samples (PD, SCZ, NA) represent subsamples from larger samples that were post-hoc matched for gender, within-scanner movement and (only for the clinical samples) age (cf.
26-1	5273-5284	Importantly	_
26-2	5285-5286	,	_
26-3	5287-5293	target	_
26-4	5294-5297	and	_
26-5	5298-5305	control	_
26-6	5306-5312	groups	_
26-7	5313-5314	(	_
26-8	5315-5319	i.e.	_
26-9	5320-5321	,	_
26-10	5322-5330	patients	_
26-11	5331-5334	vs.	_
26-12	5335-5342	healthy	_
26-13	5343-5351	controls	_
26-14	5352-5353	,	_
26-15	5354-5357	old	_
26-16	5358-5361	vs.	_
26-17	5362-5367	young	_
26-18	5368-5374	adults	_
26-19	5375-5376	)	_
26-20	5377-5379	of	_
26-21	5380-5383	all	_
26-22	5384-5389	three	_
26-23	5390-5397	samples	_
26-24	5398-5399	(	_
26-25	5400-5402	PD	_
26-26	5403-5404	,	_
26-27	5405-5408	SCZ	_
26-28	5409-5410	,	_
26-29	5411-5413	NA	_
26-30	5414-5415	)	_
26-31	5416-5425	represent	_
26-32	5426-5436	subsamples	_
26-33	5437-5441	from	_
26-34	5442-5448	larger	_
26-35	5449-5456	samples	_
26-36	5457-5461	that	_
26-37	5462-5466	were	_
26-38	5467-5475	post-hoc	_
26-39	5476-5483	matched	_
26-40	5484-5487	for	_
26-41	5488-5494	gender	_
26-42	5495-5496	,	_
26-43	5497-5511	within-scanner	_
26-44	5512-5520	movement	_
26-45	5521-5524	and	_
26-46	5525-5526	(	_
26-47	5527-5531	only	_
26-48	5532-5535	for	_
26-49	5536-5539	the	_
26-50	5540-5548	clinical	_
26-51	5549-5556	samples	_
26-52	5557-5558	)	_
26-53	5559-5562	age	_
26-54	5563-5564	(	_
26-55	5565-5567	cf	_
26-56	5568-5569	.	_

Text=Table I for sample and group matching characteristics).
27-1	5570-5575	Table	_
27-2	5576-5577	I	_
27-3	5578-5581	for	_
27-4	5582-5588	sample	_
27-5	5589-5592	and	_
27-6	5593-5598	group	_
27-7	5599-5607	matching	_
27-8	5608-5623	characteristics	_
27-9	5624-5625	)	_
27-10	5626-5627	.	_

Text=Written informed consent from all subjects and approval by the local ethics committees was obtained from all sites.
28-1	5628-5635	Written	_
28-2	5636-5644	informed	_
28-3	5645-5652	consent	_
28-4	5653-5657	from	_
28-5	5658-5661	all	_
28-6	5662-5670	subjects	_
28-7	5671-5674	and	_
28-8	5675-5683	approval	_
28-9	5684-5686	by	_
28-10	5687-5690	the	_
28-11	5691-5696	local	_
28-12	5697-5703	ethics	_
28-13	5704-5714	committees	_
28-14	5715-5718	was	_
28-15	5719-5727	obtained	_
28-16	5728-5732	from	_
28-17	5733-5736	all	_
28-18	5737-5742	sites	_
28-19	5743-5744	.	_

Text=Joint reanalysis of the anonymized data was approved by the ethics committee of the HHU Düsseldorf.
29-1	5745-5750	Joint	_
29-2	5751-5761	reanalysis	_
29-3	5762-5764	of	_
29-4	5765-5768	the	_
29-5	5769-5779	anonymized	_
29-6	5780-5784	data	_
29-7	5785-5788	was	_
29-8	5789-5797	approved	_
29-9	5798-5800	by	_
29-10	5801-5804	the	_
29-11	5805-5811	ethics	_
29-12	5812-5821	committee	_
29-13	5822-5824	of	_
29-14	5825-5828	the	_
29-15	5829-5832	HHU	_
29-16	5833-5843	Düsseldorf	_
29-17	5844-5845	.	_

Text=2.2 Resting-state fMRI data acquisition, preprocessing, and analysis During image acquisition (see Table SI for fMRI parameters), participants were instructed to lie still, let their mind wander and not fall asleep (confirmed at debriefing).
30-1	5846-5849	2.2	_
30-2	5850-5863	Resting-state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-3	5864-5868	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
30-4	5869-5873	data	_
30-5	5874-5885	acquisition	_
30-6	5886-5887	,	_
30-7	5888-5901	preprocessing	_
30-8	5902-5903	,	_
30-9	5904-5907	and	_
30-10	5908-5916	analysis	_
30-11	5917-5923	During	_
30-12	5924-5929	image	_
30-13	5930-5941	acquisition	_
30-14	5942-5943	(	_
30-15	5944-5947	see	_
30-16	5948-5953	Table	_
30-17	5954-5956	SI	_
30-18	5957-5960	for	_
30-19	5961-5965	fMRI	_
30-20	5966-5976	parameters	_
30-21	5977-5978	)	_
30-22	5979-5980	,	_
30-23	5981-5993	participants	_
30-24	5994-5998	were	_
30-25	5999-6009	instructed	_
30-26	6010-6012	to	_
30-27	6013-6016	lie	_
30-28	6017-6022	still	_
30-29	6023-6024	,	_
30-30	6025-6028	let	_
30-31	6029-6034	their	_
30-32	6035-6039	mind	_
30-33	6040-6046	wander	_
30-34	6047-6050	and	_
30-35	6051-6054	not	_
30-36	6055-6059	fall	_
30-37	6060-6066	asleep	_
30-38	6067-6068	(	_
30-39	6069-6078	confirmed	_
30-40	6079-6081	at	_
30-41	6082-6092	debriefing	_
30-42	6093-6094	)	_
30-43	6095-6096	.	_

Text=SPM8 (www.fil.ion.ucl.ac.uk/spm) was used for image realignment, spatial normalization to the MNI-152 template using the unified segmentation approach, and smoothing (5-mm full width at half maximum Gaussian).
31-1	6097-6101	SPM8	_
31-2	6102-6103	(	_
31-3	6104-6129	www.fil.ion.ucl.ac.uk/spm	_
31-4	6130-6131	)	_
31-5	6132-6135	was	_
31-6	6136-6140	used	_
31-7	6141-6144	for	_
31-8	6145-6150	image	_
31-9	6151-6162	realignment	_
31-10	6163-6164	,	_
31-11	6165-6172	spatial	_
31-12	6173-6186	normalization	_
31-13	6187-6189	to	_
31-14	6190-6193	the	_
31-15	6194-6201	MNI-152	_
31-16	6202-6210	template	_
31-17	6211-6216	using	_
31-18	6217-6220	the	_
31-19	6221-6228	unified	_
31-20	6229-6241	segmentation	_
31-21	6242-6250	approach	_
31-22	6251-6252	,	_
31-23	6253-6256	and	_
31-24	6257-6266	smoothing	_
31-25	6267-6268	(	_
31-26	6269-6273	5-mm	_
31-27	6274-6278	full	_
31-28	6279-6284	width	_
31-29	6285-6287	at	_
31-30	6288-6292	half	_
31-31	6293-6300	maximum	_
31-32	6301-6309	Gaussian	_
31-33	6310-6311	)	_
31-34	6312-6313	.	_

Text=We investigated 12 functional networks, robustly defined by previous quantitative meta-analyses, to reflect neural correlates of a broad set of cognitive, social-affective/motivational and motor functions (see Table II for an overview and Table SII for detailed network coordinates and corresponding brain regions).
32-1	6314-6316	We	_
32-2	6317-6329	investigated	_
32-3	6330-6332	12	_
32-4	6333-6343	functional	_
32-5	6344-6352	networks	_
32-6	6353-6354	,	_
32-7	6355-6363	robustly	_
32-8	6364-6371	defined	_
32-9	6372-6374	by	_
32-10	6375-6383	previous	_
32-11	6384-6396	quantitative	_
32-12	6397-6410	meta-analyses	_
32-13	6411-6412	,	_
32-14	6413-6415	to	_
32-15	6416-6423	reflect	_
32-16	6424-6430	neural	_
32-17	6431-6441	correlates	_
32-18	6442-6444	of	_
32-19	6445-6446	a	_
32-20	6447-6452	broad	_
32-21	6453-6456	set	_
32-22	6457-6459	of	_
32-23	6460-6469	cognitive	_
32-24	6470-6471	,	_
32-25	6472-6501	social-affective/motivational	_
32-26	6502-6505	and	_
32-27	6506-6511	motor	_
32-28	6512-6521	functions	_
32-29	6522-6523	(	_
32-30	6524-6527	see	_
32-31	6528-6533	Table	_
32-32	6534-6536	II	_
32-33	6537-6540	for	_
32-34	6541-6543	an	_
32-35	6544-6552	overview	_
32-36	6553-6556	and	_
32-37	6557-6562	Table	_
32-38	6563-6566	SII	_
32-39	6567-6570	for	_
32-40	6571-6579	detailed	_
32-41	6580-6587	network	_
32-42	6588-6599	coordinates	_
32-43	6600-6603	and	_
32-44	6604-6617	corresponding	_
32-45	6618-6623	brain	_
32-46	6624-6631	regions	_
32-47	6632-6633	)	_
32-48	6634-6635	.	_

Text=Only meta-analytic networks with a minimum of 10 nodes were included, since a lower number of features are uninformative for robust classification.
33-1	6636-6640	Only	_
33-2	6641-6654	meta-analytic	_
33-3	6655-6663	networks	_
33-4	6664-6668	with	_
33-5	6669-6670	a	_
33-6	6671-6678	minimum	_
33-7	6679-6681	of	_
33-8	6682-6684	10	_
33-9	6685-6690	nodes	_
33-10	6691-6695	were	_
33-11	6696-6704	included	_
33-12	6705-6706	,	_
33-13	6707-6712	since	_
33-14	6713-6714	a	_
33-15	6715-6720	lower	_
33-16	6721-6727	number	_
33-17	6728-6730	of	_
33-18	6731-6739	features	_
33-19	6740-6743	are	_
33-20	6744-6757	uninformative	_
33-21	6758-6761	for	_
33-22	6762-6768	robust	_
33-23	6769-6783	classification	_
33-24	6784-6785	.	_

Text=Resting-state functional connectivity (RSFC) within each network was computed per subject by first extracting the time-series for each node within 6 mm of the meta-analytic peaks.
34-1	6786-6799	Resting-state	_
34-2	6800-6810	functional	_
34-3	6811-6823	connectivity	_
34-4	6824-6825	(	_
34-5	6826-6830	RSFC	_
34-6	6831-6832	)	_
34-7	6833-6839	within	_
34-8	6840-6844	each	_
34-9	6845-6852	network	_
34-10	6853-6856	was	_
34-11	6857-6865	computed	_
34-12	6866-6869	per	_
34-13	6870-6877	subject	_
34-14	6878-6880	by	_
34-15	6881-6886	first	_
34-16	6887-6897	extracting	_
34-17	6898-6901	the	_
34-18	6902-6913	time-series	_
34-19	6914-6917	for	_
34-20	6918-6922	each	_
34-21	6923-6927	node	_
34-22	6928-6934	within	_
34-23	6935-6936	6	_
34-24	6937-6939	mm	_
34-25	6940-6942	of	_
34-26	6943-6946	the	_
34-27	6947-6960	meta-analytic	_
34-28	6961-6966	peaks	_
34-29	6967-6968	.	_

Text=To reduce spurious correlations, variance explained by the 6 movement parameters and their derivatives (modeled as 1st and 2nd order effects) as well as the mean white-matter and Cerebrospinal fluid signal time-courses was removed from the time series.
35-1	6969-6971	To	_
35-2	6972-6978	reduce	_
35-3	6979-6987	spurious	_
35-4	6988-7000	correlations	_
35-5	7001-7002	,	_
35-6	7003-7011	variance	_
35-7	7012-7021	explained	_
35-8	7022-7024	by	_
35-9	7025-7028	the	_
35-10	7029-7030	6	_
35-11	7031-7039	movement	_
35-12	7040-7050	parameters	_
35-13	7051-7054	and	_
35-14	7055-7060	their	_
35-15	7061-7072	derivatives	_
35-16	7073-7074	(	_
35-17	7075-7082	modeled	_
35-18	7083-7085	as	_
35-19	7086-7089	1st	_
35-20	7090-7093	and	_
35-21	7094-7097	2nd	_
35-22	7098-7103	order	_
35-23	7104-7111	effects	_
35-24	7112-7113	)	_
35-25	7114-7116	as	_
35-26	7117-7121	well	_
35-27	7122-7124	as	_
35-28	7125-7128	the	_
35-29	7129-7133	mean	_
35-30	7134-7146	white-matter	_
35-31	7147-7150	and	_
35-32	7151-7164	Cerebrospinal	_
35-33	7165-7170	fluid	_
35-34	7171-7177	signal	_
35-35	7178-7190	time-courses	_
35-36	7191-7194	was	_
35-37	7195-7202	removed	_
35-38	7203-7207	from	_
35-39	7208-7211	the	_
35-40	7212-7216	time	_
35-41	7217-7223	series	_
35-42	7224-7225	.	_

Text=Subsequently, time series were high-pass filtered retaining frequencies above 0.01 Hz.
36-1	7226-7238	Subsequently	_
36-2	7239-7240	,	_
36-3	7241-7245	time	_
36-4	7246-7252	series	_
36-5	7253-7257	were	_
36-6	7258-7267	high-pass	_
36-7	7268-7276	filtered	_
36-8	7277-7286	retaining	_
36-9	7287-7298	frequencies	_
36-10	7299-7304	above	_
36-11	7305-7309	0.01	_
36-12	7310-7312	Hz	_
36-13	7313-7314	.	_

Text=Connectivity was computed as the Fisher ’ s Z-transformed Pearson correlation between the time series of each network ’ s nodes; connectivity values were adjusted for effects of acquisition site, gender, movement, total brain volume, and (only for the clinical samples) age (cf.)
37-1	7315-7327	Connectivity	_
37-2	7328-7331	was	_
37-3	7332-7340	computed	_
37-4	7341-7343	as	_
37-5	7344-7347	the	_
37-6	7348-7354	Fisher	_
37-7	7355-7356	’	_
37-8	7357-7358	s	_
37-9	7359-7372	Z-transformed	_
37-10	7373-7380	Pearson	_
37-11	7381-7392	correlation	_
37-12	7393-7400	between	_
37-13	7401-7404	the	_
37-14	7405-7409	time	_
37-15	7410-7416	series	_
37-16	7417-7419	of	_
37-17	7420-7424	each	_
37-18	7425-7432	network	_
37-19	7433-7434	’	_
37-20	7435-7436	s	_
37-21	7437-7442	nodes	_
37-22	7443-7444	;	_
37-23	7445-7457	connectivity	_
37-24	7458-7464	values	_
37-25	7465-7469	were	_
37-26	7470-7478	adjusted	_
37-27	7479-7482	for	_
37-28	7483-7490	effects	_
37-29	7491-7493	of	_
37-30	7494-7505	acquisition	_
37-31	7506-7510	site	_
37-32	7511-7512	,	_
37-33	7513-7519	gender	_
37-34	7520-7521	,	_
37-35	7522-7530	movement	_
37-36	7531-7532	,	_
37-37	7533-7538	total	_
37-38	7539-7544	brain	_
37-39	7545-7551	volume	_
37-40	7552-7553	,	_
37-41	7554-7557	and	_
37-42	7558-7559	(	_
37-43	7560-7564	only	_
37-44	7565-7568	for	_
37-45	7569-7572	the	_
37-46	7573-7581	clinical	_
37-47	7582-7589	samples	_
37-48	7590-7591	)	_
37-49	7592-7595	age	_
37-50	7596-7597	(	_
37-51	7598-7600	cf	_
37-52	7601-7602	.	_
37-53	7603-7604	)	_

Text=to avoid classification based on spurious between-subject effects.
38-1	7605-7607	to	_
38-2	7608-7613	avoid	_
38-3	7614-7628	classification	_
38-4	7629-7634	based	_
38-5	7635-7637	on	_
38-6	7638-7646	spurious	_
38-7	7647-7662	between-subject	_
38-8	7663-7670	effects	_
38-9	7671-7672	.	_

Text=2.3 Support Vector Machine Features and Classification To examine whether the RSFC pattern of a network contains predictive information on the respective groups (SCZ vs. HCSCZ, PD vs. HCPD, old vs. young) non-sparse linear two-class SVMs were computed using LibSVM (https: //www.csie.ntu.edu.tw/~cjlin/libsvm).
39-1	7673-7676	2.3	_
39-2	7677-7684	Support	_
39-3	7685-7691	Vector	_
39-4	7692-7699	Machine	_
39-5	7700-7708	Features	_
39-6	7709-7712	and	_
39-7	7713-7727	Classification	_
39-8	7728-7730	To	_
39-9	7731-7738	examine	_
39-10	7739-7746	whether	_
39-11	7747-7750	the	_
39-12	7751-7755	RSFC	_
39-13	7756-7763	pattern	_
39-14	7764-7766	of	_
39-15	7767-7768	a	_
39-16	7769-7776	network	_
39-17	7777-7785	contains	_
39-18	7786-7796	predictive	_
39-19	7797-7808	information	_
39-20	7809-7811	on	_
39-21	7812-7815	the	_
39-22	7816-7826	respective	_
39-23	7827-7833	groups	_
39-24	7834-7835	(	_
39-25	7836-7839	SCZ	_
39-26	7840-7843	vs.	_
39-27	7844-7849	HCSCZ	_
39-28	7850-7851	,	_
39-29	7852-7854	PD	_
39-30	7855-7858	vs.	_
39-31	7859-7863	HCPD	_
39-32	7864-7865	,	_
39-33	7866-7869	old	_
39-34	7870-7873	vs.	_
39-35	7874-7879	young	_
39-36	7880-7881	)	_
39-37	7882-7892	non-sparse	_
39-38	7893-7899	linear	_
39-39	7900-7909	two-class	_
39-40	7910-7914	SVMs	_
39-41	7915-7919	were	_
39-42	7920-7928	computed	_
39-43	7929-7934	using	_
39-44	7935-7941	LibSVM	_
39-45	7942-7943	(	_
39-46	7944-7949	https	_
39-47	7950-7951	:	_
39-48	7952-7987	//www.csie.ntu.edu.tw/~cjlin/libsvm	_
39-49	7988-7989	)	_
39-50	7990-7991	.	_

Text=SVMs ’ were trained separately for each of all three analyses (PD, SCZ, NA) and each of the functional networks.
40-1	7992-7996	SVMs	_
40-2	7997-7998	’	_
40-3	7999-8003	were	_
40-4	8004-8011	trained	_
40-5	8012-8022	separately	_
40-6	8023-8026	for	_
40-7	8027-8031	each	_
40-8	8032-8034	of	_
40-9	8035-8038	all	_
40-10	8039-8044	three	_
40-11	8045-8053	analyses	_
40-12	8054-8055	(	_
40-13	8056-8058	PD	_
40-14	8059-8060	,	_
40-15	8061-8064	SCZ	_
40-16	8065-8066	,	_
40-17	8067-8069	NA	_
40-18	8070-8071	)	_
40-19	8072-8075	and	_
40-20	8076-8080	each	_
40-21	8081-8083	of	_
40-22	8084-8087	the	_
40-23	8088-8098	functional	_
40-24	8099-8107	networks	_
40-25	8108-8109	.	_

Text=Of note, we did not attempt between-patient classification (i.e., PD vs. SCZ), as the different groups were closely matched to their respective controls but substantially different from each other with respect to age, gender, and movement.
41-1	8110-8112	Of	_
41-2	8113-8117	note	_
41-3	8118-8119	,	_
41-4	8120-8122	we	_
41-5	8123-8126	did	_
41-6	8127-8130	not	_
41-7	8131-8138	attempt	_
41-8	8139-8154	between-patient	_
41-9	8155-8169	classification	_
41-10	8170-8171	(	_
41-11	8172-8176	i.e.	_
41-12	8177-8178	,	_
41-13	8179-8181	PD	_
41-14	8182-8185	vs.	_
41-15	8186-8189	SCZ	_
41-16	8190-8191	)	_
41-17	8192-8193	,	_
41-18	8194-8196	as	_
41-19	8197-8200	the	_
41-20	8201-8210	different	_
41-21	8211-8217	groups	_
41-22	8218-8222	were	_
41-23	8223-8230	closely	_
41-24	8231-8238	matched	_
41-25	8239-8241	to	_
41-26	8242-8247	their	_
41-27	8248-8258	respective	_
41-28	8259-8267	controls	_
41-29	8268-8271	but	_
41-30	8272-8285	substantially	_
41-31	8286-8295	different	_
41-32	8296-8300	from	_
41-33	8301-8305	each	_
41-34	8306-8311	other	_
41-35	8312-8316	with	_
41-36	8317-8324	respect	_
41-37	8325-8327	to	_
41-38	8328-8331	age	_
41-39	8332-8333	,	_
41-40	8334-8340	gender	_
41-41	8341-8342	,	_
41-42	8343-8346	and	_
41-43	8347-8355	movement	_
41-44	8356-8357	.	_

Text=The input variables (features) to the SVM consisted of edge-wise RSFC between all nodes of a given network.
42-1	8358-8361	The	_
42-2	8362-8367	input	_
42-3	8368-8377	variables	_
42-4	8378-8379	(	_
42-5	8380-8388	features	_
42-6	8389-8390	)	_
42-7	8391-8393	to	_
42-8	8394-8397	the	_
42-9	8398-8401	SVM	_
42-10	8402-8411	consisted	_
42-11	8412-8414	of	_
42-12	8415-8424	edge-wise	_
42-13	8425-8429	RSFC	_
42-14	8430-8437	between	_
42-15	8438-8441	all	_
42-16	8442-8447	nodes	_
42-17	8448-8450	of	_
42-18	8451-8452	a	_
42-19	8453-8458	given	_
42-20	8459-8466	network	_
42-21	8467-8468	.	_

Text=Each SVM was trained and tested by a nested 10-fold cross validation scheme for each individual group (see example Figure 1) (cf .).
43-1	8469-8473	Each	_
43-2	8474-8477	SVM	_
43-3	8478-8481	was	_
43-4	8482-8489	trained	_
43-5	8490-8493	and	_
43-6	8494-8500	tested	_
43-7	8501-8503	by	_
43-8	8504-8505	a	_
43-9	8506-8512	nested	_
43-10	8513-8520	10-fold	_
43-11	8521-8526	cross	_
43-12	8527-8537	validation	_
43-13	8538-8544	scheme	_
43-14	8545-8548	for	_
43-15	8549-8553	each	_
43-16	8554-8564	individual	_
43-17	8565-8570	group	_
43-18	8571-8572	(	_
43-19	8573-8576	see	_
43-20	8577-8584	example	_
43-21	8585-8591	Figure	_
43-22	8592-8593	1	_
43-23	8594-8595	)	_
43-24	8596-8597	(	_
43-25	8598-8600	cf	_
43-26	8601-8602	.	_
43-27	8603-8604	)	_
43-28	8605-8606	.	_

Text=The inner loop used a 10-fold cross-validation within the training group to optimize the soft-margin slack parameter.
44-1	8607-8610	The	_
44-2	8611-8616	inner	_
44-3	8617-8621	loop	_
44-4	8622-8626	used	_
44-5	8627-8628	a	_
44-6	8629-8636	10-fold	_
44-7	8637-8653	cross-validation	_
44-8	8654-8660	within	_
44-9	8661-8664	the	_
44-10	8665-8673	training	_
44-11	8674-8679	group	_
44-12	8680-8682	to	_
44-13	8683-8691	optimize	_
44-14	8692-8695	the	_
44-15	8696-8707	soft-margin	_
44-16	8708-8713	slack	_
44-17	8714-8723	parameter	_
44-18	8724-8725	.	_

Text=For each fold of the outer loop, the left-out (unseen) 10% were then classified using the SVM trained on the (entire) training-set using the optimized parameter.
45-1	8726-8729	For	_
45-2	8730-8734	each	_
45-3	8735-8739	fold	_
45-4	8740-8742	of	_
45-5	8743-8746	the	_
45-6	8747-8752	outer	_
45-7	8753-8757	loop	_
45-8	8758-8759	,	_
45-9	8760-8763	the	_
45-10	8764-8772	left-out	_
45-11	8773-8774	(	_
45-12	8775-8781	unseen	_
45-13	8782-8783	)	_
45-14	8784-8786	10	_
45-15	8787-8788	%	_
45-16	8789-8793	were	_
45-17	8794-8798	then	_
45-18	8799-8809	classified	_
45-19	8810-8815	using	_
45-20	8816-8819	the	_
45-21	8820-8823	SVM	_
45-22	8824-8831	trained	_
45-23	8832-8834	on	_
45-24	8835-8838	the	_
45-25	8839-8840	(	_
45-26	8841-8847	entire	_
45-27	8848-8849	)	_
45-28	8850-8862	training-set	_
45-29	8863-8868	using	_
45-30	8869-8872	the	_
45-31	8873-8882	optimized	_
45-32	8883-8892	parameter	_
45-33	8893-8894	.	_

Text=This nested scheme ensured that classifier optimization and evaluation was performed independent of each other.
46-1	8895-8899	This	_
46-2	8900-8906	nested	_
46-3	8907-8913	scheme	_
46-4	8914-8921	ensured	_
46-5	8922-8926	that	_
46-6	8927-8937	classifier	_
46-7	8938-8950	optimization	_
46-8	8951-8954	and	_
46-9	8955-8965	evaluation	_
46-10	8966-8969	was	_
46-11	8970-8979	performed	_
46-12	8980-8991	independent	_
46-13	8992-8994	of	_
46-14	8995-8999	each	_
46-15	9000-9005	other	_
46-16	9006-9007	.	_

Text=Classification performance was evaluated based on accuracy (Acc.
47-1	9008-9022	Classification	_
47-2	9023-9034	performance	_
47-3	9035-9038	was	_
47-4	9039-9048	evaluated	_
47-5	9049-9054	based	_
47-6	9055-9057	on	_
47-7	9058-9066	accuracy	_
47-8	9067-9068	(	_
47-9	9069-9072	Acc	_
47-10	9073-9074	.	_

Text=), balanced accuracy (bAcc.
48-1	9075-9076	)	_
48-2	9077-9078	,	_
48-3	9079-9087	balanced	_
48-4	9088-9096	accuracy	_
48-5	9097-9098	(	_
48-6	9099-9103	bAcc	_
48-7	9104-9105	.	_

Text=), sensitivity (Sens.
49-1	9106-9107	)	_
49-2	9108-9109	,	_
49-3	9110-9121	sensitivity	_
49-4	9122-9123	(	_
49-5	9124-9128	Sens	_
49-6	9129-9130	.	_

Text=), and specificity (Spec.)
50-1	9131-9132	)	_
50-2	9133-9134	,	_
50-3	9135-9138	and	_
50-4	9139-9150	specificity	_
50-5	9151-9152	(	_
50-6	9153-9157	Spec	_
50-7	9158-9159	.	_
50-8	9160-9161	)	_

Text=as well as two measures derived from signal-detection theory: the area under the receiver operating characteristics curve (AUC) and d ’.
51-1	9162-9164	as	_
51-2	9165-9169	well	_
51-3	9170-9172	as	_
51-4	9173-9176	two	_
51-5	9177-9185	measures	_
51-6	9186-9193	derived	_
51-7	9194-9198	from	_
51-8	9199-9215	signal-detection	_
51-9	9216-9222	theory	_
51-10	9223-9224	:	_
51-11	9225-9228	the	_
51-12	9229-9233	area	_
51-13	9234-9239	under	_
51-14	9240-9243	the	_
51-15	9244-9252	receiver	_
51-16	9253-9262	operating	_
51-17	9263-9278	characteristics	_
51-18	9279-9284	curve	_
51-19	9285-9286	(	_
51-20	9287-9290	AUC	_
51-21	9291-9292	)	_
51-22	9293-9296	and	_
51-23	9297-9298	d	_
51-24	9299-9300	’	_
51-25	9301-9302	.	_

Text=Acc.
52-1	9303-9306	Acc	_
52-2	9307-9308	.	_

Text=denotes the overall proportion of subjects correctly classified as patients (PD, SCZ) or advanced age versus healthy or younger age, respectively.
53-1	9309-9316	denotes	_
53-2	9317-9320	the	_
53-3	9321-9328	overall	_
53-4	9329-9339	proportion	_
53-5	9340-9342	of	_
53-6	9343-9351	subjects	_
53-7	9352-9361	correctly	_
53-8	9362-9372	classified	_
53-9	9373-9375	as	_
53-10	9376-9384	patients	_
53-11	9385-9386	(	_
53-12	9387-9389	PD	_
53-13	9390-9391	,	_
53-14	9392-9395	SCZ	_
53-15	9396-9397	)	_
53-16	9398-9400	or	_
53-17	9401-9409	advanced	_
53-18	9410-9413	age	_
53-19	9414-9420	versus	_
53-20	9421-9428	healthy	_
53-21	9429-9431	or	_
53-22	9432-9439	younger	_
53-23	9440-9443	age	_
53-24	9444-9445	,	_
53-25	9446-9458	respectively	_
53-26	9459-9460	.	_

Text=The bAcc.
54-1	9461-9464	The	_
54-2	9465-9469	bAcc	_
54-3	9470-9471	.	_

Text=is calculated as the average proportion of subjects correctly classified as patients (PD, SCZ) or advanced age versus healthy or younger age, respectively.
55-1	9472-9474	is	_
55-2	9475-9485	calculated	_
55-3	9486-9488	as	_
55-4	9489-9492	the	_
55-5	9493-9500	average	_
55-6	9501-9511	proportion	_
55-7	9512-9514	of	_
55-8	9515-9523	subjects	_
55-9	9524-9533	correctly	_
55-10	9534-9544	classified	_
55-11	9545-9547	as	_
55-12	9548-9556	patients	_
55-13	9557-9558	(	_
55-14	9559-9561	PD	_
55-15	9562-9563	,	_
55-16	9564-9567	SCZ	_
55-17	9568-9569	)	_
55-18	9570-9572	or	_
55-19	9573-9581	advanced	_
55-20	9582-9585	age	_
55-21	9586-9592	versus	_
55-22	9593-9600	healthy	_
55-23	9601-9603	or	_
55-24	9604-9611	younger	_
55-25	9612-9615	age	_
55-26	9616-9617	,	_
55-27	9618-9630	respectively	_
55-28	9631-9632	.	_

Text=Sens.
56-1	9633-9637	Sens	_
56-2	9638-9639	.	_

Text=indicates the percentage of patients (SCZ or PD) correctly classified as ill or subjects correctly classified as old in the aging sample (true positives).
57-1	9640-9649	indicates	_
57-2	9650-9653	the	_
57-3	9654-9664	percentage	_
57-4	9665-9667	of	_
57-5	9668-9676	patients	_
57-6	9677-9678	(	_
57-7	9679-9682	SCZ	_
57-8	9683-9685	or	_
57-9	9686-9688	PD	_
57-10	9689-9690	)	_
57-11	9691-9700	correctly	_
57-12	9701-9711	classified	_
57-13	9712-9714	as	_
57-14	9715-9718	ill	_
57-15	9719-9721	or	_
57-16	9722-9730	subjects	_
57-17	9731-9740	correctly	_
57-18	9741-9751	classified	_
57-19	9752-9754	as	_
57-20	9755-9758	old	_
57-21	9759-9761	in	_
57-22	9762-9765	the	_
57-23	9766-9771	aging	_
57-24	9772-9778	sample	_
57-25	9779-9780	(	_
57-26	9781-9785	true	_
57-27	9786-9795	positives	_
57-28	9796-9797	)	_
57-29	9798-9799	.	_

Text=Spec.
58-1	9800-9804	Spec	_
58-2	9805-9806	.	_

Text=in turn represents the fraction of HCs correctly classified as healthy or subjects correctly identified as young in the aging sample (true negatives).
59-1	9807-9809	in	_
59-2	9810-9814	turn	_
59-3	9815-9825	represents	_
59-4	9826-9829	the	_
59-5	9830-9838	fraction	_
59-6	9839-9841	of	_
59-7	9842-9845	HCs	_
59-8	9846-9855	correctly	_
59-9	9856-9866	classified	_
59-10	9867-9869	as	_
59-11	9870-9877	healthy	_
59-12	9878-9880	or	_
59-13	9881-9889	subjects	_
59-14	9890-9899	correctly	_
59-15	9900-9910	identified	_
59-16	9911-9913	as	_
59-17	9914-9919	young	_
59-18	9920-9922	in	_
59-19	9923-9926	the	_
59-20	9927-9932	aging	_
59-21	9933-9939	sample	_
59-22	9940-9941	(	_
59-23	9942-9946	true	_
59-24	9947-9956	negatives	_
59-25	9957-9958	)	_
59-26	9959-9960	.	_

Text=AUC refers to the area under the receiver operating characteristics (ROC) curve.
60-1	9961-9964	AUC	_
60-2	9965-9971	refers	_
60-3	9972-9974	to	_
60-4	9975-9978	the	_
60-5	9979-9983	area	_
60-6	9984-9989	under	_
60-7	9990-9993	the	_
60-8	9994-10002	receiver	_
60-9	10003-10012	operating	_
60-10	10013-10028	characteristics	_
60-11	10029-10030	(	_
60-12	10031-10034	ROC	_
60-13	10035-10036	)	_
60-14	10037-10042	curve	_
60-15	10043-10044	.	_

Text=An ROC curve depicts the relationship between true positive rate and false positive rate, and its AUC value indicates the sensitivity of the diagnostic process independent of any specific decision criterion.
61-1	10045-10047	An	_
61-2	10048-10051	ROC	_
61-3	10052-10057	curve	_
61-4	10058-10065	depicts	_
61-5	10066-10069	the	_
61-6	10070-10082	relationship	_
61-7	10083-10090	between	_
61-8	10091-10095	true	_
61-9	10096-10104	positive	_
61-10	10105-10109	rate	_
61-11	10110-10113	and	_
61-12	10114-10119	false	_
61-13	10120-10128	positive	_
61-14	10129-10133	rate	_
61-15	10134-10135	,	_
61-16	10136-10139	and	_
61-17	10140-10143	its	_
61-18	10144-10147	AUC	_
61-19	10148-10153	value	_
61-20	10154-10163	indicates	_
61-21	10164-10167	the	_
61-22	10168-10179	sensitivity	_
61-23	10180-10182	of	_
61-24	10183-10186	the	_
61-25	10187-10197	diagnostic	_
61-26	10198-10205	process	_
61-27	10206-10217	independent	_
61-28	10218-10220	of	_
61-29	10221-10224	any	_
61-30	10225-10233	specific	_
61-31	10234-10242	decision	_
61-32	10243-10252	criterion	_
61-33	10253-10254	.	_

Text=Finally, we assessed d ’, an alternative index of diagnostic sensitivity independent of the decision criterion, calculated as z (true positive rate) – z (false positive rate).
62-1	10255-10262	Finally	_
62-2	10263-10264	,	_
62-3	10265-10267	we	_
62-4	10268-10276	assessed	_
62-5	10277-10278	d	_
62-6	10279-10280	’	_
62-7	10281-10282	,	_
62-8	10283-10285	an	_
62-9	10286-10297	alternative	_
62-10	10298-10303	index	_
62-11	10304-10306	of	_
62-12	10307-10317	diagnostic	_
62-13	10318-10329	sensitivity	_
62-14	10330-10341	independent	_
62-15	10342-10344	of	_
62-16	10345-10348	the	_
62-17	10349-10357	decision	_
62-18	10358-10367	criterion	_
62-19	10368-10369	,	_
62-20	10370-10380	calculated	_
62-21	10381-10383	as	_
62-22	10384-10385	z	_
62-23	10386-10387	(	_
62-24	10388-10392	true	_
62-25	10393-10401	positive	_
62-26	10402-10406	rate	_
62-27	10407-10408	)	_
62-28	10409-10410	–	_
62-29	10411-10412	z	_
62-30	10413-10414	(	_
62-31	10415-10420	false	_
62-32	10421-10429	positive	_
62-33	10430-10434	rate	_
62-34	10435-10436	)	_
62-35	10437-10438	.	_

Text=To increase robustness, the entire procedure was repeated 25 times, and each performance measures was averaged across repetitions.
63-1	10439-10441	To	_
63-2	10442-10450	increase	_
63-3	10451-10461	robustness	_
63-4	10462-10463	,	_
63-5	10464-10467	the	_
63-6	10468-10474	entire	_
63-7	10475-10484	procedure	_
63-8	10485-10488	was	_
63-9	10489-10497	repeated	_
63-10	10498-10500	25	_
63-11	10501-10506	times	_
63-12	10507-10508	,	_
63-13	10509-10512	and	_
63-14	10513-10517	each	_
63-15	10518-10529	performance	_
63-16	10530-10538	measures	_
63-17	10539-10542	was	_
63-18	10543-10551	averaged	_
63-19	10552-10558	across	_
63-20	10559-10570	repetitions	_
63-21	10571-10572	.	_

Text=To examine significant differences in classification performance between networks within each group, pairwise t-tests were performed for each of the 12 networks based on the accuracies obtained from the 25 cross-validation outer-loop replications of the separate SVMs (significance threshold of p <0.05, Bonferroni-corrected for the number of pairwise network comparisons).
64-1	10573-10575	To	_
64-2	10576-10583	examine	_
64-3	10584-10595	significant	_
64-4	10596-10607	differences	_
64-5	10608-10610	in	_
64-6	10611-10625	classification	_
64-7	10626-10637	performance	_
64-8	10638-10645	between	_
64-9	10646-10654	networks	_
64-10	10655-10661	within	_
64-11	10662-10666	each	_
64-12	10667-10672	group	_
64-13	10673-10674	,	_
64-14	10675-10683	pairwise	_
64-15	10684-10691	t-tests	_
64-16	10692-10696	were	_
64-17	10697-10706	performed	_
64-18	10707-10710	for	_
64-19	10711-10715	each	_
64-20	10716-10718	of	_
64-21	10719-10722	the	_
64-22	10723-10725	12	_
64-23	10726-10734	networks	_
64-24	10735-10740	based	_
64-25	10741-10743	on	_
64-26	10744-10747	the	_
64-27	10748-10758	accuracies	_
64-28	10759-10767	obtained	_
64-29	10768-10772	from	_
64-30	10773-10776	the	_
64-31	10777-10779	25	_
64-32	10780-10796	cross-validation	_
64-33	10797-10807	outer-loop	_
64-34	10808-10820	replications	_
64-35	10821-10823	of	_
64-36	10824-10827	the	_
64-37	10828-10836	separate	_
64-38	10837-10841	SVMs	_
64-39	10842-10843	(	_
64-40	10844-10856	significance	_
64-41	10857-10866	threshold	_
64-42	10867-10869	of	_
64-43	10870-10871	p	_
64-44	10872-10873	<	_
64-45	10874-10878	0.05	_
64-46	10879-10880	,	_
64-47	10881-10901	Bonferroni-corrected	_
64-48	10902-10905	for	_
64-49	10906-10909	the	_
64-50	10910-10916	number	_
64-51	10917-10919	of	_
64-52	10920-10928	pairwise	_
64-53	10929-10936	network	_
64-54	10937-10948	comparisons	_
64-55	10949-10950	)	_
64-56	10951-10952	.	_

Text=To compare the separately conducted classifications for SCZ vs. HCSCZ and PD vs. HCPD subgroups, accuracies obtained for each individual analysis for every network were converted to standardized z-scores by reference to the binomial distribution reflecting chance level and corrected for multiple comparisons by the amount of networks-based classifications.
65-1	10953-10955	To	_
65-2	10956-10963	compare	_
65-3	10964-10967	the	_
65-4	10968-10978	separately	_
65-5	10979-10988	conducted	_
65-6	10989-11004	classifications	_
65-7	11005-11008	for	_
65-8	11009-11012	SCZ	_
65-9	11013-11016	vs.	_
65-10	11017-11022	HCSCZ	_
65-11	11023-11026	and	_
65-12	11027-11029	PD	_
65-13	11030-11033	vs.	_
65-14	11034-11038	HCPD	_
65-15	11039-11048	subgroups	_
65-16	11049-11050	,	_
65-17	11051-11061	accuracies	_
65-18	11062-11070	obtained	_
65-19	11071-11074	for	_
65-20	11075-11079	each	_
65-21	11080-11090	individual	_
65-22	11091-11099	analysis	_
65-23	11100-11103	for	_
65-24	11104-11109	every	_
65-25	11110-11117	network	_
65-26	11118-11122	were	_
65-27	11123-11132	converted	_
65-28	11133-11135	to	_
65-29	11136-11148	standardized	_
65-30	11149-11157	z-scores	_
65-31	11158-11160	by	_
65-32	11161-11170	reference	_
65-33	11171-11173	to	_
65-34	11174-11177	the	_
65-35	11178-11186	binomial	_
65-36	11187-11199	distribution	_
65-37	11200-11210	reflecting	_
65-38	11211-11217	chance	_
65-39	11218-11223	level	_
65-40	11224-11227	and	_
65-41	11228-11237	corrected	_
65-42	11238-11241	for	_
65-43	11242-11250	multiple	_
65-44	11251-11262	comparisons	_
65-45	11263-11265	by	_
65-46	11266-11269	the	_
65-47	11270-11276	amount	_
65-48	11277-11279	of	_
65-49	11280-11294	networks-based	_
65-50	11295-11310	classifications	_
65-51	11311-11312	.	_

Text=Log-likelihood ratios (LLRs) were estimated to identify networks showing better classification performance for one patient group than the other.
66-1	11313-11327	Log-likelihood	_
66-2	11328-11334	ratios	_
66-3	11335-11336	(	_
66-4	11337-11341	LLRs	_
66-5	11342-11343	)	_
66-6	11344-11348	were	_
66-7	11349-11358	estimated	_
66-8	11359-11361	to	_
66-9	11362-11370	identify	_
66-10	11371-11379	networks	_
66-11	11380-11387	showing	_
66-12	11388-11394	better	_
66-13	11395-11409	classification	_
66-14	11410-11421	performance	_
66-15	11422-11425	for	_
66-16	11426-11429	one	_
66-17	11430-11437	patient	_
66-18	11438-11443	group	_
66-19	11444-11448	than	_
66-20	11449-11452	the	_
66-21	11453-11458	other	_
66-22	11459-11460	.	_

Text=To investigate significant differences in classification performance between the groups, t-tests were calculated based on the 25 accuracies obtained from the cross-validation outer-loop replications of the separate SVMs performed in each group (SCZ, PD, NA) for each of the 12 networks (significance threshold of p <0.05, Bonferroni-corrected for the number of groups and networks).
67-1	11461-11463	To	_
67-2	11464-11475	investigate	_
67-3	11476-11487	significant	_
67-4	11488-11499	differences	_
67-5	11500-11502	in	_
67-6	11503-11517	classification	_
67-7	11518-11529	performance	_
67-8	11530-11537	between	_
67-9	11538-11541	the	_
67-10	11542-11548	groups	_
67-11	11549-11550	,	_
67-12	11551-11558	t-tests	_
67-13	11559-11563	were	_
67-14	11564-11574	calculated	_
67-15	11575-11580	based	_
67-16	11581-11583	on	_
67-17	11584-11587	the	_
67-18	11588-11590	25	_
67-19	11591-11601	accuracies	_
67-20	11602-11610	obtained	_
67-21	11611-11615	from	_
67-22	11616-11619	the	_
67-23	11620-11636	cross-validation	_
67-24	11637-11647	outer-loop	_
67-25	11648-11660	replications	_
67-26	11661-11663	of	_
67-27	11664-11667	the	_
67-28	11668-11676	separate	_
67-29	11677-11681	SVMs	_
67-30	11682-11691	performed	_
67-31	11692-11694	in	_
67-32	11695-11699	each	_
67-33	11700-11705	group	_
67-34	11706-11707	(	_
67-35	11708-11711	SCZ	_
67-36	11712-11713	,	_
67-37	11714-11716	PD	_
67-38	11717-11718	,	_
67-39	11719-11721	NA	_
67-40	11722-11723	)	_
67-41	11724-11727	for	_
67-42	11728-11732	each	_
67-43	11733-11735	of	_
67-44	11736-11739	the	_
67-45	11740-11742	12	_
67-46	11743-11751	networks	_
67-47	11752-11753	(	_
67-48	11754-11766	significance	_
67-49	11767-11776	threshold	_
67-50	11777-11779	of	_
67-51	11780-11781	p	_
67-52	11782-11783	<	_
67-53	11784-11788	0.05	_
67-54	11789-11790	,	_
67-55	11791-11811	Bonferroni-corrected	_
67-56	11812-11815	for	_
67-57	11816-11819	the	_
67-58	11820-11826	number	_
67-59	11827-11829	of	_
67-60	11830-11836	groups	_
67-61	11837-11840	and	_
67-62	11841-11849	networks	_
67-63	11850-11851	)	_
67-64	11852-11853	.	_

